San Diego Business Journal

Holding All The Cards

BIOTECH: J&J Puts Money, Subsidiary Behind ViaCyte’s Diabetes Efforts By Brittany Meiling Originally published February 11, 2016 at 11:32 a.m., updated February 11, 2016 at 11:32 a.m.
   
ViaCyte CEO Paul Laikind holds two thin capsules, one for humans, another for lab mice, that contain insulin-producing cells. The therapy could significantly alter the quality of life for people with type 1 diabetes.

ViaCyte CEO Paul Laikind holds two thin capsules, one for humans, another for lab mice, that contain insulin-producing cells. The therapy could significantly alter the quality of life for people with type 1 diabetes.

— Johnson & Johnson is joining forces with San Diego-based ViaCyte Inc...

Prev

Page 1 of 2.

Take 1 minute to subscribe and you’ll get this story immediately, plus:

Already a subscriber? Sign in

  • 51 weekly issues: $153 value
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives: $150 value
  • Book of Lists — the biggest, hottest companies in San Diego: $75 value
  • NEW: San Diego 500 — influential business leaders you need to know: $50 value
  • Total Package Value: $428

Yours for only $129